# Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia

> **NCT07095127** · PHASE2 · RECRUITING · sponsor: **Nuvig Therapeutics, Inc.** · enrollment: 10 (estimated)

## Conditions studied

- Immune Thrombocytopenia (ITP)

## Interventions

- **DRUG:** NVG-2089

## Key facts

- **NCT ID:** NCT07095127
- **Lead sponsor:** Nuvig Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-30
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07095127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07095127, "Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07095127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*